Conditions: High Risk Stage III Melanoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1211
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: ipilimumab intervention 2: Placebo
Intervention descriptions: intervention 1: IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal intervention 2: IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal

Protocol document: